



Cancer Reporting in California

Appendix F **Site-Specific Data Items (SSDIs)**

California Cancer Reporting System Standards, Volume I: Abstracting and Coding Procedures

Twenty-Sixth Edition

Released, January 2026

Prepared By:

California Cancer Registry

Cancer Informatics and IT Systems Unit

Editors:

Mary K. Brant, B.S., ODS-C

Donna M. Hansen, ODS-C

Janine Smith, B.S., ODS-C

State of California:

Department of Health Services

Dr. Mark Damesyn, CDRSB, Chief

Appendix F: Index to Site-Specific Data Items (SSDIs)

A Site-Specific Data Item (SSDI) is based on primary site, AJCC chapter, the EOD schema, or the Summary Stage schema. SSDI's have their own data item name and number and can be collected for as many sites, chapters, and/or schemas as needed. Each Site-Specific Data Item (SSDI) applies only to selected schemas.

Source: The [Site-Specific Data Item \(SSDI\) Manual](#) is to be used for detailed descriptions, rationales, coding instructions, and site-specific coding rules.

CCR Specific Guidelines

- **The list below includes all SSDI data items required by the CCR from CoC Facilities for the current reporting year only.**
 - For requirements from previous years, please refer to the [historical Volume I](#) documentation, organized by diagnosis year.
 - Non-CoC facilities may choose to voluntarily collect CoC required SSDIs.
- **CCR follows NPCR and SEER requirements for SSDIs not mentioned in the list below.** See [NAACCR Required Status Table](#) for NPCR and SEER requirements.
- All SSDIs must be supported by text documentation in the abstract.

SSDI Data Items Required by CCR from CoC Facilities - Current Reporting Year

SSDI Data Item Name
Adenoid Cystic Basaloid Pattern
AFP Post-Orchiectomy Lab Value
AFP Post-Orchiectomy Range
AFP Pre-Orchiectomy Lab Value
AFP Pre-Orchiectomy Range
AFP Pretreatment Interpretation
AFP Pretreatment Lab Value
Bilirubin Pretreatment Total Lab Value
Bilirubin Pretreatment Unit of Measure
Bone Invasion
Clinical Margin Width
Creatinine Pretreatment Lab Value
Creatinine Pretreatment Unit of Measure
Estrogen Receptor Percent Positive or Range
Extranodal Extension Clin (non-Head and Neck)

Extranodal Extension Head and Neck Clinical
Extranodal Extension Head and Neck Pathological
Extranodal Extension Path (non-Head and Neck)
FIGO Stage
Gleason Tertiary Pattern
hCG Post-Orchiectomy Lab Value
hCG Post-Orchiectomy Range
hCG Pre-Orchiectomy Lab Value
hCG Pre-Orchiectomy Range
High Risk Histologic Features
International Normalized Ratio Prothrombin Time
Invasion Beyond Capsule
Ipsilateral Adrenal Gland Involvement
KIT Gene Immunohistochemistry
LDH Lab Value
LDH Post-Orchiectomy Range
LDH Pre-Orchiectomy Range
LDH Upper Limits of Normal
LN Assessment Method Femoral-Inguinal
LN Assessment Method Para-Aortic
LN Assessment Method Pelvic
LN Distant Assessment Method
LN Distant Mediastinal, Scalene
LN Head and Neck Levels I-III
LN Head and Neck Levels IV-V
LN Head and Neck Levels VI-VII
LN Head and Neck Other
LN Isolated Tumor Cells (ITC)
LN Size
Macroscopic Evaluation of Mesorectum
Major Vein Involvement
Mitotic Count Uveal Melanoma
NCCN International Prognostic Index (IPI)

Number of Examined Para-Aortic Nodes
Number of Examined Pelvic Nodes
Number of Positive Para-Aortic Nodes
Number of Positive Pelvic Nodes
Profound Immune Suppression
Progesterone Receptor Percent Positive or Range
Residual Cancer Burden (RCB) - NEW 2026
Residual Cancer Burden Class - NEW 2026
Residual Tumor Volume Post Cytoreduction
Response to Neoadjuvant Therapy
Separate Tumor Nodules
Spread Through Air Spaces (STAS) - NEW 2026
Tumor Deposits
Visceral and Parietal Pleural Invasion